References / Safety standards
PEMF is an FDA-approved adjunct for bone healing
Regulatory standardNon-implantable PEMF bone growth stimulators are FDA-approved as an adjunct to primary treatment for nonunion fractures and, in some cases, spinal fusion. That approval is for a defined orthopedic indication under medical supervision, and it does not extend to the general-wellness PEMF devices most buyers encounter.
Where it appears in the report: Wellness-device vs. medical-device framing; certification context
The evidence
The first PEMF bone growth stimulator, the Bio-Osteogen System 204, received FDA premarket approval (PMA P790002) on November 6, 1979 for nonunion fractures, and the approved indications for this device type also include use as an adjunct to spinal fusion. These went through the FDA premarket-approval (PMA) pathway and were regulated as Class III medical devices; in 2020 the FDA reclassified non-invasive bone growth stimulators to Class II. Either way they are approved medical devices for a specific orthopedic indication, a separate regulatory category from the general-wellness PEMF devices sold to most consumers. An FDA approval for orthopedic nonunion is not a blanket endorsement of PEMF for wellness use.
Primary sources
- U.S. FDA Premarket Approval database, PMA P790002 (Stimulator, bone growth, non-invasive), approved November 6, 1979. view
- Physical Medicine Devices; Reclassification of Non-Invasive Bone Growth Stimulators. Federal Register (Aug. 17, 2020); documents PMA P790002 / Bio-Osteogen System 204 (1979) and the Class III to Class II reclassification. view